The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Left or biventricular dysfunction/failure
Publications
Bevacizumab: A Rare Cause of Nonischemic Cardiomyopathy.
Case reports in cardiology 2018;2018;1361326 — 2018 — 1361326
Cardiogenic syncope possibly related to bevacizumab-containing combination chemotherapy for advanced non-small cell lung cancer.
Journal of thoracic disease 2016 Sep;8;2646-2650 — 2016 Sep — 2646-2650
Cardiotoxicity in patients treated with bevacizumab is potentially reversible.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011 Jun 20;29;e560-2 — 2011 Jun 20 — e560-2